News | November 06, 2025
Teva reports 11th consecutive quarter of growth
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The event will be attended by 35,000+ industry professionals
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Subscribe To Our Newsletter & Stay Updated
